vs

Side-by-side financial comparison of Dragonfly Energy Holdings Corp. (DFLI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Dragonfly Energy Holdings Corp. is the larger business by last-quarter revenue ($13.1M vs $12.5M, roughly 1.0× Avidity Biosciences, Inc.). Dragonfly Energy Holdings Corp. runs the higher net margin — -344.9% vs -1398.3%, a 1053.5% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 6.9%). Dragonfly Energy Holdings Corp. produced more free cash flow last quarter ($-14.9M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 2.2%).

Dragonfly Energy Holdings Corp. is a U.S.-based energy technology company specializing in designing and manufacturing high-performance, sustainable lithium-ion batteries. Its core offerings include deep-cycle batteries for RVs, marine uses, off-grid power systems, and residential energy storage, primarily serving consumer and small industrial renewable energy markets across North America.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

DFLI vs RNA — Head-to-Head

Bigger by revenue
DFLI
DFLI
1.0× larger
DFLI
$13.1M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+427.1% gap
RNA
434.0%
6.9%
DFLI
Higher net margin
DFLI
DFLI
1053.5% more per $
DFLI
-344.9%
-1398.3%
RNA
More free cash flow
DFLI
DFLI
$142.0M more FCF
DFLI
$-14.9M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
2.2%
DFLI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DFLI
DFLI
RNA
RNA
Revenue
$13.1M
$12.5M
Net Profit
$-45.0M
$-174.4M
Gross Margin
18.2%
Operating Margin
-78.1%
-1513.5%
Net Margin
-344.9%
-1398.3%
Revenue YoY
6.9%
434.0%
Net Profit YoY
-357.6%
-117.0%
EPS (diluted)
$-13.09
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DFLI
DFLI
RNA
RNA
Q4 25
$13.1M
Q3 25
$16.0M
$12.5M
Q2 25
$16.2M
$3.8M
Q1 25
$13.4M
$1.6M
Q4 24
$12.2M
$3.0M
Q3 24
$12.7M
$2.3M
Q2 24
$13.2M
$2.0M
Q1 24
$12.5M
$3.5M
Net Profit
DFLI
DFLI
RNA
RNA
Q4 25
$-45.0M
Q3 25
$-11.1M
$-174.4M
Q2 25
$-7.0M
$-157.3M
Q1 25
$-6.8M
$-115.8M
Q4 24
$-9.8M
$-102.3M
Q3 24
$-6.8M
$-80.4M
Q2 24
$-13.6M
$-70.8M
Q1 24
$-10.4M
$-68.9M
Gross Margin
DFLI
DFLI
RNA
RNA
Q4 25
18.2%
Q3 25
29.7%
Q2 25
28.3%
Q1 25
29.4%
Q4 24
20.8%
Q3 24
22.6%
Q2 24
24.0%
Q1 24
24.4%
Operating Margin
DFLI
DFLI
RNA
RNA
Q4 25
-78.1%
Q3 25
-23.7%
-1513.5%
Q2 25
-20.2%
-4448.7%
Q1 25
-44.3%
-8360.9%
Q4 24
-58.5%
-4069.6%
Q3 24
-47.4%
-4200.9%
Q2 24
-51.1%
-4040.4%
Q1 24
-46.7%
-2178.6%
Net Margin
DFLI
DFLI
RNA
RNA
Q4 25
-344.9%
Q3 25
-69.3%
-1398.3%
Q2 25
-43.3%
-4089.3%
Q1 25
-50.9%
-7360.0%
Q4 24
-80.6%
-3439.5%
Q3 24
-53.3%
-3441.7%
Q2 24
-103.2%
-3461.8%
Q1 24
-82.9%
-1943.4%
EPS (diluted)
DFLI
DFLI
RNA
RNA
Q4 25
$-13.09
Q3 25
$-0.20
$-1.27
Q2 25
$-0.58
$-1.21
Q1 25
$-0.93
$-0.90
Q4 24
$-54.60
$-0.80
Q3 24
$-0.11
$-0.65
Q2 24
$-0.22
$-0.65
Q1 24
$-0.17
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DFLI
DFLI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$18.3M
$350.2M
Total DebtLower is stronger
$19.3M
Stockholders' EquityBook value
$11.5M
$1.9B
Total Assets
$86.5M
$2.1B
Debt / EquityLower = less leverage
1.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DFLI
DFLI
RNA
RNA
Q4 25
$18.3M
Q3 25
$3.8M
$350.2M
Q2 25
$2.7M
$243.9M
Q1 25
$2.5M
$254.2M
Q4 24
$4.8M
$219.9M
Q3 24
$8.0M
$370.2M
Q2 24
$4.7M
$575.8M
Q1 24
$8.5M
$471.4M
Total Debt
DFLI
DFLI
RNA
RNA
Q4 25
$19.3M
Q3 25
$97.1M
Q2 25
$93.2M
Q1 25
$89.5M
Q4 24
$85.9M
Q3 24
$82.4M
Q2 24
$80.4M
Q1 24
$77.1M
Stockholders' Equity
DFLI
DFLI
RNA
RNA
Q4 25
$11.5M
Q3 25
$-21.6M
$1.9B
Q2 25
$-16.6M
$1.2B
Q1 25
$-15.6M
$1.3B
Q4 24
$-9.4M
$1.4B
Q3 24
$-297.0K
$1.5B
Q2 24
$5.3M
$1.2B
Q1 24
$17.8M
$830.9M
Total Assets
DFLI
DFLI
RNA
RNA
Q4 25
$86.5M
Q3 25
$73.8M
$2.1B
Q2 25
$71.8M
$1.4B
Q1 25
$74.2M
$1.5B
Q4 24
$75.2M
$1.6B
Q3 24
$83.9M
$1.6B
Q2 24
$85.0M
$1.3B
Q1 24
$88.4M
$951.5M
Debt / Equity
DFLI
DFLI
RNA
RNA
Q4 25
1.68×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
15.27×
Q1 24
4.33×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DFLI
DFLI
RNA
RNA
Operating Cash FlowLast quarter
$-14.7M
$-156.2M
Free Cash FlowOCF − Capex
$-14.9M
$-156.9M
FCF MarginFCF / Revenue
-113.8%
-1257.6%
Capex IntensityCapex / Revenue
1.1%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DFLI
DFLI
RNA
RNA
Q4 25
$-14.7M
Q3 25
$-156.2M
Q2 25
$-199.7M
Q1 25
$-4.5M
$-124.8M
Q4 24
$-2.5M
$-99.9M
Q3 24
$-65.6M
Q2 24
$-65.0M
Q1 24
$-3.4M
$-70.4M
Free Cash Flow
DFLI
DFLI
RNA
RNA
Q4 25
$-14.9M
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-5.3M
$-128.6M
Q4 24
$-3.5M
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-4.2M
$-71.3M
FCF Margin
DFLI
DFLI
RNA
RNA
Q4 25
-113.8%
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-39.6%
-8174.3%
Q4 24
-28.6%
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-33.7%
-2012.3%
Capex Intensity
DFLI
DFLI
RNA
RNA
Q4 25
1.1%
Q3 25
5.7%
Q2 25
86.9%
Q1 25
5.8%
238.6%
Q4 24
8.1%
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
6.5%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DFLI
DFLI

Original Equipment Manufacturers$8.1M62%
Sales Channel Directly To Consumer$4.7M36%

RNA
RNA

Segment breakdown not available.

Related Comparisons